

**INDIANA HEALTH COVERAGE PROGRAMS (IHCP) PHARMACY BENEFIT  
AGENTS FOR CUSHING'S SYNDROME PRIOR AUTHORIZATION REQUEST FORM**



**CareSource Pharmacy Prior Authorization Form**

**P.O. Box 8738  
Dayton, OH 45401-8738  
Fax: (866) 930-0019**

Today's Date

/  /

Non-Urgent ☐

Urgent ☐

**Note:** This form must be completed by the prescribing provider.

**\*\*\*All sections must be completed or the request will be returned.\*\*\***

Patient's CareSource #

Date of Birth  /  /

Patient's Name

Prescriber's Name

Prescriber's IN License #

Prescriber's Specialty

Prescriber's NPI #

Office Contact

Prescriber's Fax  -  -

Prescriber's Phone  -  -

Prescriber's Address

Date(s) of Service: \_\_\_\_\_  
Start Date: \_\_\_\_\_

**Requested Medication & Strength**

**Quantity**

**Directions for Use**

**Duration of Therapy:**

**Is the patient currently receiving this therapy?** ☐ Yes ☐ No

**If yes, please note the Start Date:**  /  /

**Physician Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_

**PA Requirements for Isturisa (osilodrostat phosphate)**

1. Member is  $\geq 18$  years of age? ☐ Yes ☐ No
2. Diagnosis of Cushing's syndrome not treatable by or responsive to pituitary surgery? ☐ Yes ☐ No  
Diagnosis Code: \_\_\_\_\_
3. Member is currently utilizing pimozide (contraindicated)? ☐ Yes ☐ No
4. Dose requested is 60 mg/day or less? ☐ Yes ☐ No

#### PA Requirements for Korlym (mifepristone)

1. Member is  $\geq 18$  years of age? ☐ Yes ☐ No
2. Diagnosis of hyperglycemia secondary to endogenous Cushing's syndrome in patients who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not a candidate for surgery? ☐ Yes ☐ No      Diagnosis Code: \_\_\_\_\_
3. Member is currently utilizing any of the following contraindicated agents: simvastatin, lovastatin, CYP3A substrates with narrow therapeutic ranges (e.g. cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, etc.), systemic corticosteroids being utilized for life saving purposes (e.g., immunosuppression following organ transplant)? ☐ Yes ☐ No
4. Member has been diagnosed with any of the following contraindications to therapy: women with a history of unexplained vaginal bleeding, endometrial hyperplasia with atypia, or endometrial carcinoma? ☐ Yes ☐ No
5. Member has had a negative pregnancy test in the past 30 days? ☐ Yes ☐ No  
Date of negative pregnancy test (include documentation): \_\_\_\_\_
6. Prescriber has counseled member on risks associated with conceiving while utilizing mifepristone and appropriate methods of non-hormonal contraception? ☐ Yes ☐ No
7. Dose requested is 1200 mg/day or less? ☐ Yes ☐ No

#### PA Requirements for Lysodren (mitotane)

1. Please select member's diagnosis:  
☐ Cushing's syndrome      Diagnosis Code: \_\_\_\_\_  
☐ Inoperable adrenocortical cancer      Diagnosis Code: \_\_\_\_\_
2. Member is  $\geq 18$  years of age? ☐ Yes ☐ No
3. Member has had a negative pregnancy test in the past 30 days? ☐ Yes ☐ No  
Date of negative pregnancy test (include documentation): \_\_\_\_\_
4. Dose requested is 10 g/day or less? ☐ Yes ☐ No

#### PA Requirements for Metopirone (metyrapone)

1. Please select member's diagnosis  
☐ Cushing's syndrome      Diagnosis Code: \_\_\_\_\_  
☐ Pituitary-dependent hypercortisolism      Diagnosis Code: \_\_\_\_\_  
☐ Requiring diagnostic testing of HPA hormone function      Diagnosis Code: \_\_\_\_\_
2. Member is  $\geq 18$  years of age (for all indications except diagnostic testing)? ☐ Yes ☐ No
3. Dose requested is 6 g/day or less? ☐ Yes ☐ No

#### PA Requirements for Recorlev (levoketoconazole)

1. Member is  $\geq 18$  years of age? ☐ Yes ☐ No
2. Diagnosis of hypercortisolemia in patients with Cushing's syndrome who have failed results from surgery or cannot have surgery ☐ Yes ☐ No Diagnosis Code: \_\_\_\_\_
3. Dose requested is 1.2 g/day or less ☐ Yes ☐ No

#### PA Requirements for Signifor (pasireotide diaspartate)

1. Please select member's diagnosis:      Diagnosis Code: \_\_\_\_\_
  - ☐ Cushing's syndrome not treatable by or unresponsive to pituitary surgery
  - ☐ Prevention of post-operative pancreatic fistula, leak, or abscess in patients undergoing pancreaticoduodenectomy or distal pancreatectomy
2. Member is  $\geq 18$  years of age?    ☐ Yes ☐ No
3. Dose requested is 2.4 mg/day or less?    ☐ Yes ☐ No

#### PA Requirements for Signifor LAR (pasireotide pam oate)

1. Please select member's diagnosis:      Diagnosis code: \_\_\_\_\_
  - ☐ Cushing's syndrome not treatable by or unresponsive to pituitary surgery
  - ☐ Acromegaly with inadequate response to surgery or surgery is not an option
  - ☐ Carcinoid syndrome inadequately controlled with first-generation somatostatin analog
2. Member is  $\geq 18$  years of age?    ☐ Yes ☐ No
3. Dose requested is one of the following:
  - a. 40 mg every 4 weeks for the diagnosis of Cushing's syndrome    ☐ Yes ☐ No
  - b. 60 mg every 4 weeks for the diagnosis of acromegaly or carcinoid syndrome  
☐ Yes ☐ No

#### CONFIDENTIAL INFORMATION

This facsimile and any attached document are confidential and are intended for the use of individual or entity to which it is addressed. If you have received this in error, please notify us by telephone immediately at **1-844-607-2831**.